The AMDA is partnering with Medlive to bring this exciting program to HCPs in the Pompe community.
Join leading experts Dr. Tahseen Mozaffar and Dr. Barbara Burton as they discuss late-onset Pompe disease (LOPD)A form of Pompe disease that begins after infancy and usually progresses more slowly. More. Hear the latest advancements, including newly approved therapies, diagnostic challenges, and strategies for team-based care. This engaging session also features a patient perspective, highlighting unmet needs and challenges in managing LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More.
Watch on Medlive Neuro.
Program Details:
Title: Newly Available Therapies to Improve Mobility and Respiratory Outcomes in Late-onset Pompe DiseaseA form of Pompe disease that begins after infancy and usually progresses more slowly. More: Early Diagnosis and Treatment Selection
Launch Date: November 21, 2024
Program Expiration: November 21, 2025
Intended Audience: Neurologists, pediatric neurologists, pediatricians, orthopedists, physical therapists, respiratory specialists, and other HCPs involved in the care of Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More.
Program Description:
Misdiagnosis is common in late-onset Pompe disease (LOPD)A form of Pompe disease that begins after infancy and usually progresses more slowly. More, which often leads to delays in treatment. Clinicians must be aware of the early signs and symptoms of LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More as well as the latest safety and efficacy data in order to facilitate the timely diagnosis of this disease. Join a panel led by expert neurologists Dr. Tahseen Mozaffar and Dr. Barbara Burton to discuss diagnostic criteria and testing for LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More, newly approved therapeutic options, and how patients with LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More will also highlight unmet challenges in care from a patient’s perspective.
Learning Objectives:
- Use available diagnostic criteria and tests, including GAA function/activity testing and genetic testingA test that looks for changes in a person's genes, including changes in the GAA gene. More, to facilitate the timely diagnosis of late-onset Pompe disease (LOPD)A form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Describe the most recent safety and efficacy data with newly approved therapies for patients with LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Develop individualized management plans that incorporate a team-based approach to care and shared decision-making for patients with LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
Topics of Interest:
- Raising the index of suspicion in LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Epidemiology and pathogenesis of LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Early signs and symptoms
- Differentiation between IOPDA severe form of Pompe disease that begins in infancy and often affects the heart and muscles. More and LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Diagnostic Challenges
- Novel therapies for LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Newly approved therapeutic options
- Elucidating a neurologist’s role in team-based care and shared decision-making for better outcomes in LOPDA form of Pompe disease that begins after infancy and usually progresses more slowly. More
- Encouraging patients to actively participate in care decisions, addressing barriers to care
Faculty:
Tahseen Mozaffar, MD
Professor of Neurology and Pathology
Director, Division of Neuromuscular Medicine
Director, UC Irvine-MDA ALS and Neuromuscular Center
Department of Neurology
Barbara K. Burton, MD
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Genetics, Genomics and Metabolism
Ann & Robert H. Lurie Children’s Hospital of Chicago